Drug intelligence / Profile preview

SLS-008

Development stage: Preclinical
Lead developer: Seelos Therapeutics
Modality: Small Molecules
Administration: Oral

Overview

SLS-008 is a small molecule, orally bioavailable antagonist of the prostaglandin D2 (PGD2) receptor, specifically targeting the chemoattractant receptor-homologous molecule expressed on TH2 cells (CRTH2). It is developed for the treatment of atopic dermatitis, pediatric esophagitis, and asthma. Initially developed by Ligand Pharmaceuticals, it is currently in the preclinical phase of development.

Other names: SLS008SLS-008SLS 008

Targets

PTGDR2 (Prostaglandin D2 receptor 2)

Beyond the preview

Go deeper on SLS-008.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on SLS-008.

Explore the full profile